A new novolimus-eluting bioresorbable coronary scaffold: Present status and future clinical perspectives.
Sign Up to like & getrecommendations! Published in 2017 at "International journal of cardiology"
DOI: 10.1016/j.ijcard.2016.11.033
Abstract: The DESolve® scaffold (Elixir Medical Corporation, Sunnyvale, California, USA) is manufactured from a poly-l-lactide based polymer and elutes an anti-proliferative, anti-inflammatory drug, Novolimus from a poly-l-lactide based topcoat mixture. The strut thickness is 150μm and… read more here.
Keywords: new novolimus; bioresorbable coronary; coronary scaffold; novolimus eluting ... See more keywords
TCT-330 Multi-Center Evaluation of a Novel 120 μm Novolimus-Eluting, Fully Bioresorbable Coronary Scaffold: First Report of 6-month Imaging and 12-Month Clinical Results
Sign Up to like & getrecommendations! Published in 2017 at "Journal of the American College of Cardiology"
DOI: 10.1016/j.jacc.2017.09.418
Abstract: The DESolve Cx study is a prospective, multi-center evaluation of the safety and efficacy of the DESolve® Cx Novolimus-Eluting Bioresorbable Coronary Scaffold System (BCSS) using clinical endpoints and multiple imaging modalities. The DESolve Cx BCSS… read more here.
Keywords: multi center; bioresorbable coronary; coronary scaffold; novolimus eluting ... See more keywords